Solventum Corporation (SOLV)
Healthcare · Medical - Instruments & Supplies · Data as of 2026-10-22
Bottom line
SOLV is trading near its usual valuation, near its historical resistance zone, and recent volume shows no clear direction. The picture is mixed, so it may be worth watching rather than acting on. Past patterns are not a guarantee of future results.
Valuation — Cheap-looking, with quality flags (Yellow)
SOLV trades at 11× earnings, roughly in line with its own 5-year average of 10× and below similar healthcare companies we track (28×, 53 peers). Historically this has been on the cheaper side for the stock. On next year's expected earnings (9 analyst estimates), it trades at 12× — still above its historical average.
Quality check: the business reported positive earnings but negative free cash flow over the last year — a gap that often traces to working capital absorbing cash.
Price zones — Near its historical resistance zone (Red)
At $87.45, the stock is close to the upper end of its recent range. Over the past year SOLV has traded between $62.38 and $94.16; its historical support zone sits near $78.37 and resistance near $88.59. It is above one of its moving averages and below the other — a mixed trend picture.
52-week range $62.38–$94.16 · 50-day average $88.59 · 200-day average $78.37
Money flow — No clear direction (Yellow)
Buying and selling volume in SOLV have been fairly balanced recently, with no strong accumulation or distribution pattern. Volume on up days has been about 1.3× volume on down days over the last 30 sessions.
Dividends & company facts
SOLV doesn't pay a dividend, and it bought back no shares in fiscal 2025. Its share count fell 0.5% over the past year.
- Shares, past year
- -0.5%
- Revenue, 12 months
- $8.3B
- Profit, 12 months
- $1.4B
- Employees
- 20,584
- CEO
- Bryan C. Hanson
- Headquarters
- Eagan, MN
- Listed since
- 2024 · NYSE
About the company
Solventum Corporation, established in 2023 and headquartered in Saint Paul, Minnesota, operates as a healthcare entity dedicated to pioneering, producing, and commercializing diverse solutions that address critical needs for both customers and patients. The company's business activities are organized into four principal segments. The Medsurg division furnishes various products and services, including sophisticated wound care items, intravenous (I.V.) site management tools, sterilization assurance systems, temperature regulation devices, surgical instruments, stethoscopes, and medical…
Related stocks
一句话结论
SOLV 估值接近其惯常水平，接近其历史阻力区，近期成交量没有明确方向。整体情况好坏参半，也许更适合先观察，而不是急于行动。过去的形态并不能保证未来的结果。
估值 — 看似便宜，但有质量警示
SOLV 目前的市盈率为 11×，大致持平于其自身 5 年平均的 10×，并且低于我们追踪的同类Healthcare公司（28×，53 家）。从历史来看，这属于该股较便宜的一侧。按明年的预期盈利计算（9 位分析师的预测），其市盈率为 12×，仍高于历史平均水平。
质量核对：过去一年公司报告了正的利润，但自由现金流为负——这样的差距常常源于营运资金占用了现金。
价格区间 — 接近其历史阻力区
目前价格为 $87.45，接近其近期区间的上沿。过去一年 SOLV 的价格在 $62.38 到 $94.16 之间波动；其历史支撑区在 $78.37 附近，阻力区在 $88.59 附近。它位于其中一条均线上方、另一条下方——趋势信号并不一致。
资金流向 — 方向不明确
SOLV 近期的买卖成交量大致均衡，没有明显的吸筹或派发形态。过去 30 个交易日，上涨日的成交量约为下跌日的 1.3×。
股息与公司概况
SOLV 不派发股息，并且在 2025 财年没有回购股票。其股数过去一年减少了 0.5%。
UnderTheLight 用直白的语言解释股票——估值、价格区间与资金流向。它只描述数据，不构成任何投资建议。
UnderTheLight explains stocks in plain English — valuation, price zones and money flow as traffic lights, recomputed nightly. It describes data; it is not investment advice and never recommends a trade.